China-based ATLATL Innovation Center, a global innovation platform for life science research and development, has announced an agreement with Japan's Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the Asia-Pacific (APAC) biotech sector to help Daiichi Sankyo identify high-quality R&D platform technologies and accelerate the transformation and implementation of innovative science in order to potentially bring new treatment options to patients worldwide.
As a builder of life science innovation ecosystems, ATLATL has developed a one-stop global innovation platform based on its engineered life science "Super Server" model, integrating R&D infrastructure, technical services, and investment support.
With innovation R&D centers in Shanghai, Beijing, Shenzhen, Hong Kong, Singapore, and other strategic hubs, ATLATL operates a connected network across core APAC markets, enabling scalable and cross-border biopharmaceutical innovation. It efficiently connects high-quality biotech startups, growth-stage companies, and scientific research forces in the region.
With its mature incubation system and refined operation capabilities, ATLATL provides clients with full-chain services from resource matching and technical support to cooperation implementation, serving as a crucial bridge linking global innovation resources.
